Actual Reason Why Cannabis Stock Failed to Interest Stockholders in 2020
The global cannabis industry is thriving and attracting a lot of investment. As more research is done into the medicinal and therapeutic usage of cannabis, the market is only expected to develop. The research and development of cannabis based medicines and therapeutic products is not only beneficial for the cannabis industry but it is also kickstarting peripheral industries that are based on the by products created by the cannabis industry. As a result, hemp-based renewable sources of energy are also being developed.
The potential therefore in this industry is immense and this is why there is a global trend towards the legalisation of medicinal and recreational uses of cannabis. The situation in Australia is a bit different. Australia has one of the highest consumption rates of cannabis in the world, people consume it for both medicinal and recreational uses.
Owing to this high usage, in 2016 the law-making medicinal cannabis legal was passed. This was landmark legislation that was seen as a precursor to the complete legalisation of cannabis in Australia.
Read More: Initial Public Offering on the ASX
NewZealand Referendum Repercussions
New Zealand also felt this paradigm shift and called for a referendum to legalise cannabis. The referendum in New Zealand however ended in a decline, which means that New Zealand is not going to legalise recreational usage of cannabis.
Why is this important for Australia? Australia and New Zealand share a lot of things, the cannabis consumption pattern is one of those shared things. Although New Zealand declined to legalise cannabis, this result, however, came with a very narrow margin. The same can be said for Australia, although no referendum has taken place in Australia public opinion can be gauged from the New Zealand referendum.
The negative referendum in New Zealand, in turn negatively affects the Australian cannabis industry because the major players and key investors feel this as a potential threat. Why? Australia currently has very conservative laws when it comes to the usage of medicinal cannabis.
Although the usage for medicinal purposes is legalised the process for getting a license to cultivate and produce medicinal products is wrought with obstacles and difficulties. The costs of getting a license in Australia far outweigh the benefits for now and this is one of the foremost concerns of the manufacturers and investors.
The barriers for entry are far too high at the moment, almost as if the legalisation is only on paper and not intended to be seen through. Due to this, the cannabis industry in Australia is facing impediments in growth. Four years on and there is still a severe dearth of research, development and logistic infrastructure for this industry.
Change in Investor Behavior
This is why 2020 has not been a very positive year for the cannabis stocks in Australia. One reason for this dismal performance has been the change in plan for many overseas cannabis firms that had invested in Australia.
AusCann group lost the investment backing by Canopy Growth, which resulted in almost 13.2% interest in AusCann group being sold. This translates to almost $6 million worth of loss of investment. Similarly, Athea group holdings are also on the path of losing the support of NYSE listed Aphria.
The reason why international investors are pulling out of the Australian cannabis industry is because of its competitive advantage. Australia has delayed its response to opening up the economy to legal cannabis, as a result, there is no local infrastructure, as discussed above. During the last 5-6 years, other countries have developed their infrastructure thereby gaining a competitive advantage.
What this means is that cultivating cannabis is simply cheaper in other countries and therefore the investors no longer see Australia as a cannabis cultivator. They have therefore taken out their investments, this however does not mean that Australia has no hope. No Australia still has state of the art research and development facilities, which can allow Australia to gain a competitive advantage in research and development.
So this is why Australian cannabis stocks have not done very well. This dismal performance was further exacerbated by the global financial crisis that hit every sector including the cannabis sector as well.
All has not been bad however, there have been positive developments as well in the cannabis sector. The sector has shown steady growth, in Q1 of 2019 there were 52 approved products in the market and this figure jumped to 76 by Q3.
In addition to this local investors are also entering the market. EcoFibre is a Queensland based biotech stock, which produces hemp-based products. The products of EcoFibre are fully compliant and legal. EcoFibre also has a presence in the USA, with further growth aims.
Botanix is another local player that is currently developing CBD based medicines for the skin. Their products are in the final human trial stage.
Investors should therefore not worry about the future of the cannabis sector in Australia. There are a few obstacles when it comes to legislation and these are expected to be removed over time.
Read More: Top 5 Cannabis Stock in ASX
What is the 10 year average return on the ASX?
On average, the S&P/ASX 200 Index has returned 9.3 percent annually over the past decade.